---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021215"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:26:41.186027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Equillium Q1 net loss narrows to $3.9M; cash $62M funds into 2025; Ono partnership revenue $8.9M

## Summary
- Net loss of $3.9M ($0.11 per share) vs $37.4M loss in Q1 2022; decrease due to Ono revenue and no Bioniz acquisition costs.
- Cash, cash equivalents and short-term investments $62.0M as of March 31, 2023, expected to fund operations into 2025.
- Revenue of $8.9M from itolizumab development funding and amortization of upfront from Ono partnership.
- Clinical milestones: EQ101 Phase 2 alopecia areata initial data 2H 2023; itolizumab EQUALISE lupus nephritis topline data 1H 2024; EQUATOR aGVHD interim review 2024.
- Ono option exercise payment of ~$37M (5 billion yen) if exercised, would significantly extend cash runway.

## SEC filing metadata
- accession: 0000950170-23-021215
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017023021215/0000950170-23-021215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017023021215/eq-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021215
- JSON: https://secwatch.observer/filing/0000950170-23-021215.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021215.txt

## Key facts
- Earnings Releases
  Equillium, Inc. reported the first quarter ended March 31, 2023 results: revenue $8.9 million, net income $3.9 million, EPS $(0.11) per basic and diluted share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $8.9 million
  - Net income: $3.9 million
  - EPS: $(0.11) per basic and diluted share
  - Result: reported results
  source text: nephritis topline data anticipated in 1H 2024, EQUATOR aGVHD interim review anticipated in 2024 First Quarter 2023 Financial Results Revenue for the first quarter of 2023 was $8.9 million and was derived from itolizumab development funding from Ono Pharmaceutical Co, Ltd. (Ono) and amortization of the upfront payment from Ono. Research and development (R&D)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746466/000095017023021215/0000950170-23-021215-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.